JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Justin Walsh has given his Buy rating due to a combination of factors surrounding TriSalus Life Sciences’ promising developments and strategic expansions. The company is actively broadening the use cases for its TriNav systems, particularly in interventional radiology, which has shown clinical benefits in procedures like uterine artery embolization. This approach not only enhances the speed and effectiveness of treatments compared to traditional methods but also opens up new potential applications, such as knee embolization, which could drive further market adoption.
Furthermore, despite a slight miss in revenue expectations for the third quarter of 2025, the company has demonstrated significant year-over-year growth in unique ordering accounts and remains committed to achieving substantial revenue growth for the full year. The launch of new products, including the TriNav FLX, and the expectation of reaching adjusted EBITDA positivity in the first half of 2026, further solidify the company’s growth trajectory and potential, justifying the Buy rating.
In another report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $11.00 price target.